Single agent and synergistic combinatorial efficacy of first-in-class small molecule imipridone ONC201 in hematological malignancies

ONC201, founding member of the imipridone class of small molecules, is currently being evaluated in advancer cancer clinical trials. We explored single agent and combinatorial efficacy of ONC201 in preclinical models of hematological malignancies. ONC201 demonstrated (GI50 1–8 µM) dose- and time-dep...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cell Cycle
Hauptverfasser: Prabhu, Varun V., Talekar, Mala K., Lulla, Amriti R., Kline, C. Leah B., Zhou, Lanlan, Hall, Junior, Van den Heuvel, A. Pieter J., Dicker, David T., Babar, Jawad, Grupp, Stephan A., Garnett, Mathew J., McDermott, Ultan, Benes, Cyril H., Pu, Jeffrey J., Claxton, David F., Khan, Nadia, Oster, Wolfgang, Allen, Joshua E., El-Deiry, Wafik S.
Format: Artigo
Sprache:Inglês
Veröffentlicht: Taylor & Francis 2018
Schlagworte:
Reports
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5927637/
https://ncbi.nlm.nih.gov/pubmed/29157092
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15384101.2017.1403689
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge